Dott.ssa Carmen Mignogna

Endocrinologo, Diabetologo Altro

Roma 1 indirizzo

Prenota una visita

Invia messaggio

Prenota una visita

Invia messaggio

Prenota una visita

Indirizzo

Sicurmedical Center

Via dei Castani 183, Roma

(mappa)

Vedi mappa

Pazienti senza assicurazione sanitaria

06 2329..... Mostra numero

Visita diabetologica • 80 €

Visita endocrinologica • 80 €

Visita endocrinologica + ecografia tiroidea • 130 €

Prestazioni e prezzi

I prezzi indicati sono quelli per pazienti senza assicurazione sanitaria

Prestazioni suggerite

Visita diabetologica

Via dei Castani 183, Roma

80 €

Sicurmedical Center

Visita endocrinologica

Via dei Castani 183, Roma

80 €

Sicurmedical Center

Altre prestazioni

Visita endocrinologica + ecografia tiroidea

Via dei Castani 183, Roma

130 €

Sicurmedical Center

Esperienze

Su di me

Medico specialista in Endocrinologia e Diabetologia
La Dottoressa effettua visite specialistiche, anche avvalendosi della diagnostica per immag...

Mostra tutta la descrizione

Patologie trattate

Mostra tutte le patologie

Formazione

Dip. di Medicina e Scienze della Salute “Vincenzo Tiberio” (Molise,2008)

Specializzazioni

Diabetologia
Endocrinologia

Foto

Competenze linguistiche

Italiano

Mostra tutte le informazioni

Pubblicazioni e articoli

Pubblicazioni (21)

Livelli aumentati di sclerostina in corso di diabete mellito tipo 2 e complicanze macrovascolari (2018)

Espressione di sclerostina nelle placche aterosclerotiche di pazienti sottoposti a tea carotidea (2018)

Chitotriosidase Activity Is Inversely Associated with Diastolic Blood Pressure and HbA1c but Not with Arterial Stiffness in Patients with Type 2 Diabetes without Complications (2019)

Cardiometabolic multimorbidity is associated with a worse Covid-19 prognosis than individual cardiometabolic risk factors. A multicentre retrospective study (CoViDiab II) (2020)

Clinical features of patients with type 2 diabetes with and without Covid-19: a case control study (CoViDiab I) (2020)

Adult-onset autoimmune diabetes in 2020: An update (2020)

Investigational therapies targeting CD3 for prevention and treatment of type 1 diabetes (2021)

Impact of cardiovascular disease on clinical outcomes in hospitalized patients with Covid-19. a systematic review and meta-analysis (2021)

Short-term safety profile of Sars-Cov2 vaccination on glucose control. Continuous glucose monitoring data in people with autoimmune diabetes (2021)

Effects of the COVID-19 lockdown on glycaemic control in subjects with type 2 diabetes: the glycalock study (2021)

Decrease of coronary heart disease risk with GLP1-receptor agonists or SGLT2 inhibitors therapy in patients with type 2 diabetes in primary cardiovascular prevention: A 24 months follow-up study (2021)

Reduced early response to SARS-CoV2 vaccination in people with type 1 and type 2 diabetes, a six months follow-up study: The CoVaDiab study I (2022)

Diastolic Pressure And Acr Are Modifiable Risk Factors Of Arterial Stiffness In T2DM Without Cardiovascular Disease (2022)

Development of a clinical risk score to predict death in patients with COVID-19 (2022)

MASLD, hepatic steatosis and fibrosis are associated with the prevalence of chronic kidney disease and retinopathy in adults with type 1 diabetes mellitus (2023)

Association between different modalities of insulin administration and metabolic dysfunction-associated fatty liver disease in adults with type 1 diabetes mellitus (2023)

Hepatic steatosis with significant fibrosis is associated with an increased 10-year estimated risk of cardiovascular disease in adults with type 1 diabetes mellitus (2023)

Lack of Association between Serum Chitotriosidase Activity and Arterial Stiffness in Type 2 Diabetes without Cardiovascular Complications (2023)

Short-term effectiveness of dapagliflozin versus {DPP}-4 inhibitors in elderly patients with type 2 diabetes: a multicentre retrospective study (2023)

Sex Differences in Cardiovascular Disease and Cardiovascular Risk Estimation in Patients With Type 1 Diabetes (2023)

Saxagliptin/dapagliflozin is non‐inferior to insulin glargine in terms of β‐cell function in subjects with latent autoimmune diabetes in adults: A 12‐month, randomized, comparator‐controlled pilot study (2024)

Recensioni in arrivo

Scrivi la prima recensione

Hai avuto una visita con Dott.ssa Carmen Mignogna? Condividi quello che pensi. Grazie alla tua esperienza gli altri pazienti potranno scegliere il miglior dottore per loro.

Aggiungi una recensione